For overweight patients with poorly controlled type 2 diabetes, the advantages of weight-loss surgery for treating their disease persist over the long term, researchers have found.
The findings are drawn from randomized trial data from the largest cohort of patients with type 2 diabetes to date, with the longest period of follow-up, they reported at the annual meeting of the American Diabetes Association in San Diego.
At seven to 12 years after enrollment, surgery led to better control of blood sugar, with less medication use and higher rates of diabetes remission compared to medication and lifestyle changes, the researchers found.
Surgery patients had higher rates of anemia, gastrointestinal side effects and fractures afterward, however.
The findings confirm the results of shorter-term studies, the researchers said.
“The longer the study duration, the stronger the message in terms of remission of type 2 diabetes,” study leader John Kirwan of the Pennington Biomedical Research Center said in a statement.
His team tracked participants in four earlier randomized trials in which 195 patients had been assigned to undergo weight-loss surgery – either gastric bypass, sleeve gastrectomy, or gastric banding – and 121 had been assigned to receive medical and lifestyle therapies.
Seven years after enrollment, diabetes remission rates were 18.2% in the surgery group (down from 51% at one year) and 6.2% in the medication/lifestyle group (up from 0.5% at one year).
The surgery group had lost more weight: 19.9%, on average, vs 8.3% in the medical/lifestyle group.
And levels of hemoglobin A1c, a marker of blood sugar control, averaged 1.1% lower in the surgery group, despite use of fewer anti-diabetes medications.
Results were similar regardless of whether patients’ degree of overweight or obesity was lower that the usual eligibility cutoff for weight-loss surgery, the researchers said.